title: A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children.
abstract: In the Sahel, most malaria deaths occur among children 1-4 years old during a short transmission season. A trial of seasonal intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine (SP) and a single dose of artesunate (AS) showed an 86% reduction in the incidence of malaria in Senegal but this may not be the optimum regimen. We compared this regimen with three alternatives.
  
  
  METHODS
  2102 children aged 6-59 months received either one dose of SP plus one dose of AS (SP+1AS) (the previous regimen), one dose of SP plus 3 daily doses of AS (SP+3AS), one dose of SP plus three daily doses of amodiaquine (AQ) (SP+3AQ) or 3 daily doses of AQ and AS (3AQ+3AS). Treatments were given once a month on three occasions during the malaria transmission season. The primary end point was incidence of clinical malaria. Secondary end-points were incidence of adverse events, mean haemoglobin concentration and prevalence of parasites carrying markers of resistance to SP.
  
  
  RESULTS
  The incidence of malaria, and the prevalence of parasitaemia at the end of the transmission season, were lowest in the group that received SP+3AQ: 10% of children in the group that received SP+1AS had malaria, compared to 9% in the SP+3AS group (hazard ratio HR 0.90, 95%CI 0.60, 1.36); 11% in the 3AQ+3AS group, HR 1.1 (0.76-1.7); and 5% in the SP+3AQ group, HR 0.50 (0.30-0.81). Mutations associated with resistance to SP were present in almost all parasites detected at the end of the transmission season, but the prevalence of Plasmodium falciparum was very low in the SP+3AQ group.
  
  
  CONCLUSIONS
  Monthly treatment with SP+3AQ is a highly effective regimen for seasonal IPT. Choice of this regimen would minimise the spread of drug resistance and allow artemisinins to be reserved for the treatment of acute clinical malaria.
authors.affiliation: Institut de Recherche pour le Développement, Dakar, Senegal. sokhna@ird.sn
authors.forename: Cheikh
authors.initials: C
authors.lastname: Sokhna
authors.forename: Badara
authors.initials: B
authors.lastname: Cissé
authors.forename: El Hadj
authors.initials: el H
authors.lastname: Bâ
authors.forename: Paul
authors.initials: P
authors.lastname: Milligan
authors.forename: Rachel
authors.initials: R
authors.lastname: Hallett
authors.forename: Colin
authors.initials: C
authors.lastname: Sutherland
authors.forename: Oumar
authors.initials: O
authors.lastname: Gaye
authors.forename: Denis
authors.initials: D
authors.lastname: Boulanger
authors.forename: Kirsten
authors.initials: K
authors.lastname: Simondon
authors.forename: François
authors.initials: F
authors.lastname: Simondon
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Targett
authors.forename: Jo
authors.initials: J
authors.lastname: Lines
authors.forename: Brian
authors.initials: B
authors.lastname: Greenwood
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Trape
mesh_terms: D000655:Amodiaquine / Q000008:administration & dosage* / Q000009:adverse effects; D000962:Antimalarials / Q000008:administration & dosage* / Q000009:adverse effects; D018053:Arsenites / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D004338:Drug Combinations; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D008288:Malaria / Q000517:prevention & control*; D011739:Pyrimethamine / Q000008:administration & dosage* / Q000009:adverse effects; D012621:Seasons; D012675:Senegal; D013413:Sulfadoxine / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000962:Antimalarials; D018053:Arsenites; D004338:Drug Combinations; D000655:Amodiaquine; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; C015001:arsenite; D011739:Pyrimethamine